Migranal (Dihydroergotamine Mesilate)

Dihydroergotamine acts as a partial agonist and antagonist at serotonin 5‑HT1B and 5‑HT1D receptors. By stimulating these receptors it causes constriction of intracranial blood vessels and blocks the release of vasoactive neuropeptides, which together reduce the neurogenic inflammation and pain that trigger migraine.

The prescribed dose of Migranal is determined by the treating physician. The product delivers 1 mg of dihydroergotamine per spray, and the prescriber decides the number of sprays and timing based on the individual’s migraine pattern and response.

Safety data for dihydroergotamine in pregnancy and lactation are limited. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the risk. Breastfeeding mothers should consult their healthcare provider before use.

To order Migranal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative for acute migraine is the triptan class, such as sumatriptan. While triptans are selective 5‑HT1B/1D agonists, dihydroergotamine has a broader receptor profile, offering additional vasoconstrictive and anti‑neuropeptide effects. Choice depends on individual response, contraindications, and physician preference.

Migranal should be stored at room temperature, below 25 °C, in its original packaging. Keep the nasal spray bottle tightly closed, protect it from moisture and direct sunlight, and avoid freezing. Do not use the product after the expiration date printed on the label.

Migranal is administered as a nasal spray. The patient should gently blow the nose, insert the spray tip into one nostril, and press the actuator to deliver a single spray (1 mg). The dose may be repeated in the other nostril if directed by the prescriber, typically within a short interval.

Serious risks include severe hypertension, coronary or peripheral vasospasm, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients should be alert for chest pain, sudden severe headache, visual changes, or signs of an allergic reaction and seek immediate medical attention if they occur.

Migranal is contraindicated in patients with uncontrolled hypertension, known coronary artery disease, peripheral vascular disease, history of ergotism, or hypersensitivity to ergot alkaloids. It should also be avoided in individuals taking other ergot derivatives or potent vasoconstrictors, and in pregnant women unless clearly indicated.